BC Week In Review | Jul 4, 2011
Company News

Intrexon management update

Intrexon Corp. , Blacksburg, Va.   Business: Cancer   Hired: Glenn Nedwin as SVP and president of the human therapeutics division, formerly EVP of the Genencor International Inc. division of Danisco A/S , which was acquired by...
BC Innovations | Apr 14, 2011
Tools & Techniques

Removing immunotoxin immunogenicity

Researchers at the National Cancer Institute have developed an approach to decrease the immunogenicity of therapeutic proteins that involves identifying and removing immunogenic B cell epitopes. 1 As proof of concept, the group applied its...
BC Week In Review | Jan 28, 2008
Company News

Martek board of directors update

Martek Biosciences Corp. (NASDAQ:MATK), Columbia, Md.   Business: Nutraceuticals, Supply/Service   Appointed: Robert Mayer, former CEO and chairman of Danisco A/S 's Genencor International Inc. subsidiary  ...
BC Week In Review | Oct 8, 2007
Company News

Dyadic International management update

Dyadic International Inc. (DIL), Jupiter, Fla.   Business: Genomics, Supply/Service, Biomanufacturing   Resigned: Glenn Nedwin as a director, EVP, interim president and CSO and president of DIL's BioPharma business, to become EVP of Technical Enzymes...
BioCentury | Jun 4, 2007
Finance

Ebb & Flow

Biogen Idec (BIIB) took a step last week to get the amounts of cash and debt on its balance sheet more in line with its peer group, announcing a $3 billion stock buyback. The company...
BC Week In Review | Apr 9, 2007
Company News

Danisco, Pfizer deal

Danisco's Genencor International Inc. subsidiary granted PFE a non-exclusive license to I-Biotech technology for manufacturing secreted proteins in microorganisms. Further terms were not disclosed. Danisco A/S , Copenhagen, Denmark   Pfizer Inc. (PFE), New York, N.Y....
BC Week In Review | Oct 30, 2006
Company News

Genencor, Protein Polymer deal

The partners amended a 2001 deal under which GCOR has an exclusive worldwide license to use PPTI's protein polymer design and production technology for industrial and personal care applications (see BioCentury, Jan. 1, 2001). The...
BC Week In Review | Oct 9, 2006
Company News

Oxxon, Bavarian Nordic A/, Danisco, Novartis, Oxford BioMedica, sanofi-aventis, Therion infectious news

Oxxon said the Opposition Division of the European Patent Office (EPO) narrowed the claims of Oxxon's European Patent No. EPO979284 in an opposition that was brought by BAVA, SAN, OXB, Therion, Danisco subsidiary Genencor International...
BC Week In Review | Jun 26, 2006
Company News

Danisco sales and marketing update

Danisco's Genencor International Inc. subsidiary (Palo Alto, Calif.) launched Fermgen, an acid fungal enzyme, for use in the ethanol industry. Danisco A/S , Copenhagen, Denmark   Business: Infectious  ...
BC Week In Review | May 22, 2006
Company News

Cambridge Antibody, AstraZeneca deal

AZN agreed to buy the 80.8% of CAT it does not already own for 1,320p per share in cash, or £567 million ($1 billion). The price is a 67% premium to CAT's close of 791p...
Items per page:
1 - 10 of 200
BC Week In Review | Jul 4, 2011
Company News

Intrexon management update

Intrexon Corp. , Blacksburg, Va.   Business: Cancer   Hired: Glenn Nedwin as SVP and president of the human therapeutics division, formerly EVP of the Genencor International Inc. division of Danisco A/S , which was acquired by...
BC Innovations | Apr 14, 2011
Tools & Techniques

Removing immunotoxin immunogenicity

Researchers at the National Cancer Institute have developed an approach to decrease the immunogenicity of therapeutic proteins that involves identifying and removing immunogenic B cell epitopes. 1 As proof of concept, the group applied its...
BC Week In Review | Jan 28, 2008
Company News

Martek board of directors update

Martek Biosciences Corp. (NASDAQ:MATK), Columbia, Md.   Business: Nutraceuticals, Supply/Service   Appointed: Robert Mayer, former CEO and chairman of Danisco A/S 's Genencor International Inc. subsidiary  ...
BC Week In Review | Oct 8, 2007
Company News

Dyadic International management update

Dyadic International Inc. (DIL), Jupiter, Fla.   Business: Genomics, Supply/Service, Biomanufacturing   Resigned: Glenn Nedwin as a director, EVP, interim president and CSO and president of DIL's BioPharma business, to become EVP of Technical Enzymes...
BioCentury | Jun 4, 2007
Finance

Ebb & Flow

Biogen Idec (BIIB) took a step last week to get the amounts of cash and debt on its balance sheet more in line with its peer group, announcing a $3 billion stock buyback. The company...
BC Week In Review | Apr 9, 2007
Company News

Danisco, Pfizer deal

Danisco's Genencor International Inc. subsidiary granted PFE a non-exclusive license to I-Biotech technology for manufacturing secreted proteins in microorganisms. Further terms were not disclosed. Danisco A/S , Copenhagen, Denmark   Pfizer Inc. (PFE), New York, N.Y....
BC Week In Review | Oct 30, 2006
Company News

Genencor, Protein Polymer deal

The partners amended a 2001 deal under which GCOR has an exclusive worldwide license to use PPTI's protein polymer design and production technology for industrial and personal care applications (see BioCentury, Jan. 1, 2001). The...
BC Week In Review | Oct 9, 2006
Company News

Oxxon, Bavarian Nordic A/, Danisco, Novartis, Oxford BioMedica, sanofi-aventis, Therion infectious news

Oxxon said the Opposition Division of the European Patent Office (EPO) narrowed the claims of Oxxon's European Patent No. EPO979284 in an opposition that was brought by BAVA, SAN, OXB, Therion, Danisco subsidiary Genencor International...
BC Week In Review | Jun 26, 2006
Company News

Danisco sales and marketing update

Danisco's Genencor International Inc. subsidiary (Palo Alto, Calif.) launched Fermgen, an acid fungal enzyme, for use in the ethanol industry. Danisco A/S , Copenhagen, Denmark   Business: Infectious  ...
BC Week In Review | May 22, 2006
Company News

Cambridge Antibody, AstraZeneca deal

AZN agreed to buy the 80.8% of CAT it does not already own for 1,320p per share in cash, or £567 million ($1 billion). The price is a 67% premium to CAT's close of 791p...
Items per page:
1 - 10 of 200